E.j.d. Van Cutsem

E.j.d. Van Cutsem's AcademicInfluence.com Rankings

E.j.d. Van Cutsem

Philosophy

#8329

World Rank

#11686

Historical Rank

Logic

#5363

World Rank

#6756

Historical Rank

philosophy Degrees

Download Badge

Philosophy

E.j.d. Van Cutsem's Degrees

PhD Biomedical Sciences University of Oxford

Why Is E.j.d. Van Cutsem Influential?

(Suggest an Edit or Addition)

(See a Problem?)

E.j.d. Van Cutsem's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (2010) (5682)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (2113)
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer (1998) (994)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (2016) (864)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (2018) (791)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (2011) (768)
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group (2006) (652)
Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial (2010) (647)
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience (2008) (418)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC (2009) (403)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials (2004) (399)
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor) (1999) (343)
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial (2007) (305)
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone (1990) (273)
Gastric cancer (2016) (173)
Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer (2012) (173)
Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. (2005) (163)
Perioperative FOLFOX 4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC 40983 ) : long-term results of a randomised , controlled , phase 3 trial (2013) (152)
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. (2019) (148)
Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) (2005) (137)
Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). (2013) (136)
Impact of Interval between Neoadjuvant Chemoradiotherapy and TME for Locally Advanced Rectal Cancer on Pathologic Response and Oncologic Outcome (2012) (135)
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. (2013) (130)
Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development (2010) (127)
Large deletions of the APC gene in 15% of mutation‐negative patients with classical polyposis (FAP): A Belgian study (2005) (123)
The multidisciplinary management of gastrointestinal cancer (2007) (118)
Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data (2007) (118)
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (2019) (115)
Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. (2017) (110)
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. (2014) (104)
The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study (2012) (104)
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) (2008) (98)
Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT) (2012) (94)
Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. (2010) (94)
51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325) (2003) (92)
EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. (2013) (90)
A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). (2016) (84)
Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC) (2005) (81)
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). (2015) (78)
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811 (2020) (78)
Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases☆ (2001) (73)
1088 Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study 40986 (2003) (72)
KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. (2018) (72)
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements (2020) (69)
Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. (1995) (67)
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial (2013) (66)
New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer (2010) (65)
O-018Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC) (2015) (62)
Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). (2014) (61)
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. (2016) (60)
Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. (2010) (59)
Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer (2005) (57)
A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. (2015) (57)
Intravenous (IF) Aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCC): Results of a multinational phase III trial (EFC10262-VELOUR) (2011) (57)
386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers (2017) (56)
Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS). (2010) (54)
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) (2016) (53)
A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (2008) (53)
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. (2021) (53)
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. (2021) (52)
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia (2011) (52)
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. (2019) (51)
Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial (2010) (51)
Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (2007) (51)
MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). (2016) (49)
Acute and long-term gastrointestinal consequences of chemotherapy (2009) (49)
Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. (2018) (47)
Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). (2013) (46)
Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. (2020) (45)
BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers. (2018) (44)
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy (2014) (44)
Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer (2006) (44)
HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). (2020) (43)
6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status (2009) (42)
Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series (2008) (42)
The best manuscript: Open-label phase 3 trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[含解説者コメント] (2007) (42)
Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. (2013) (41)
Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). (2014) (41)
KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2016) (40)
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). (2014) (40)
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) (2012) (40)
804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab (2011) (40)
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. (2005) (40)
Tcf-3 expression and β -catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour) (2001) (39)
[Breast cancer in the early stage]. (2012) (39)
5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study) (2009) (38)
Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials (2007) (38)
The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes (2004) (38)
Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. (2007) (37)
The role of chemotherapy in the current treatment of gastric cancer (2002) (37)
Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer. (2017) (36)
LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer (2020) (36)
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6. (2018) (36)
803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC) (2011) (34)
Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial. (2014) (34)
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer (2007) (33)
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. (2021) (33)
RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. (2018) (33)
Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. (2013) (33)
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane (2006) (33)
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. (2016) (32)
Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer (2005) (32)
A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results (2008) (31)
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study) (2012) (31)
LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (2015) (31)
Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma (2013) (31)
Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer (2005) (31)
Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC) (2011) (31)
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839) (2003) (31)
7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy (2007) (30)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. (2019) (30)
279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin (2004) (29)
Observation of the propagation direction of human electrogastric activity from cutaneous recordings (1989) (29)
Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT (2008) (29)
Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. (2012) (28)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. (2020) (28)
The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061. (2020) (28)
Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966 (2008) (28)
Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy (2014) (28)
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. (2020) (27)
Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. (2018) (27)
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial. (2020) (27)
Genetic markers of bevacizumab-induced hypertension (2014) (26)
KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. (2016) (26)
RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. (2021) (25)
Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. (2015) (25)
Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy (2005) (25)
Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC) (2011) (25)
Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study (2006) (25)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer. (2005) (25)
Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. (2015) (24)
Perineal Colostomy with Appendicostomy as an Alternative for an Abdominal Colostomy: Symptoms, Functional Status, Quality of Life, and Perceived Health (2007) (24)
Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer. (2015) (24)
Impact of Prior Chemothe rapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors A Subgroup Analysis of the Phase III RADIANT-3 Trial (2014) (24)
A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer (2011) (23)
Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation (2011) (23)
3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy (2007) (23)
LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) (2015) (22)
7BA Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the Phase III ToGA trial (2009) (21)
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study (2009) (21)
Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD) (2002) (21)
Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications (2016) (21)
P8 Screening for a geriatric risk profile in older cancer patients: a comparative study of the predictive validity of three screening tools (2009) (21)
Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2). (2017) (21)
PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis (2014) (21)
Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial (2007) (20)
Successful treatment of human papillomavirus (HPV) associated giant squamous papilloma of the hypopharynx and esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) (1994) (20)
Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy. (2020) (20)
Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials (2007) (20)
KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab (2007) (20)
Long‐term effect of hormonal therapy for bleeding gastrointestinal vascular malformations (1993) (20)
A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients (2004) (19)
Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. (2013) (19)
The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061. (2020) (19)
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial. (2016) (19)
Georges Brohee Prize. Oestrogen-progesterone, a new therapy of bleeding gastrointestinal vascular malformations. (1993) (18)
Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. (2008) (18)
Epidermal Growth Factor ReceptorActivity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combinationwith Chemotherapy (2005) (18)
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. (2018) (18)
Randomized phase II study of weekly 24 h infusion of high dose 5-FU ± folinic acid (HD-FU±FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953 (2001) (18)
A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs) (2008) (18)
Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). (2012) (18)
High Amphiregulin and Epiregulin expression in K-ras wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease (2007) (17)
Time course of regorafenib-associated adverse events in the phase III CORRECT study. (2013) (17)
Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA). (2020) (17)
Squamous papillomatosis of the oesophagus with malignant degeneration and demonstration of the human papilloma virus (1991) (16)
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. (2019) (16)
A randomized open-label phase II study of Everolimus alone or in combination with Pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial (2015) (16)
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). (2021) (16)
3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study (2007) (16)
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups. (2015) (16)
Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). (2010) (16)
CCR New Strategies Clinical Cancer Research New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer (2010) (16)
Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer. (2016) (15)
1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab (2011) (15)
Persisting anorectal dysfunction after rectal cancer surgery (2013) (15)
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. (2014) (14)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. (2019) (14)
FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements. (2020) (14)
Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. (2016) (14)
O-0022RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (RECOURSE) (2014) (14)
Time course of regorafenib-associated adverse events in the phase III CORRECT study (2013) (14)
Emerging therapies for orphan tumors: neuroendocrine tumors (2008) (14)
The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
Germline Mutations of the hMLH1 and hMSH2 Mismatch Repair Genes in Belgian Hereditary Nonpolyposis Colon Cancer (HNPCC) Patients (2005) (14)
Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. (2017) (14)
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC). (2017) (14)
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study. (2021) (14)
HER2 positivity in advanced gastric cancer is comparable to breast cancer (2007) (14)
Three-year survival result of CORE (Capecitabine, Oxaliplatin, Radiotherapy and Excision) study after post-operative chemotherapy in patients with locally advanced rectal adenocarcinoma (2009) (13)
Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER). (2017) (13)
The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri (2008) (13)
A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). (2015) (13)
PD-0024 Phase I/II Study of Folfiri Plus the MEK1/2 Inhibitor Pimasertib (MSC1936369B) as Second-Line Treatment for KRAS Mutated Metastatic Colorectal Cancer (2012) (13)
16LBA VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer (2009) (13)
Medical resource use in a phase III trial (SO 14796) of XelodaTM (capecitabine) in previously untreated advanced/metastatic colorectal cancer (1999) (13)
Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. (2021) (13)
2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy (2015) (13)
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers (2017) (13)
MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). (2021) (13)
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study. (2019) (13)
Molecular markers in colon cancer have a stage specific prognostic value. results of the translational study on the petacc 3-eortc 40883-sakk 60-00 trial (2009) (13)
Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study (2001) (12)
O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial (2012) (12)
Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). (2018) (12)
Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies. (2020) (12)
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071) (2018) (12)
TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial. (2015) (12)
Adjuvant chemotherapy alone versus chemoradiation after curative resection for pancreatic cancer : feasibility results of a randomised EORTC/FFCD/GERCOR phase II/III study (40013/22012/0304) (2008) (12)
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses (2016) (12)
An international phase II study of Capecitabine, Oxaliplatin, Radiotherapy and Excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results. (2005) (12)
Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results (2008) (12)
MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress. (2021) (12)
CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). (2017) (12)
Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias. (2015) (11)
Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial. (2016) (11)
Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. (2013) (11)
Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC). (2013) (11)
CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA (2012) (11)
6502 A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts) (2009) (11)
Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data. (2012) (11)
Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update. (2021) (11)
Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202. (2021) (11)
Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial (2012) (11)
CPT11 alternating with 5 fluorouracil (5 FU) folinic acid (FA): A multicentre phase II study in 1st line chemotherapy (CT) of metastatic colorectal cancer (CRC): Preliminary results (1997) (10)
Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region. (2020) (10)
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors (2012) (10)
Regorafenib for metastatic colorectal cancer – Authors' reply (2013) (10)
Oral Capeci tabine Compared With Intravenous Fluorourac i l Plus Leucovor in in Pat ients With Metastat ic Colorecta l Cancer : Resul ts of a Large Phase III Study (2001) (10)
5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study (2015) (10)
6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial (2009) (10)
Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial. (2016) (10)
Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST). (2007) (10)
Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study (2009) (10)
Hand-foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC). (2017) (10)
Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC) (2010) (10)
Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial. (2015) (10)
ADJUVANT FOLFOX4 PLUS OR MINUS CETUXIMAB (CMAB) IN PATIENTS (PTS) WITH KRAS MUTANT (MKRAS) RESECTED STAGE III COLON CANCER (CC). RESULTS FROM THE PETACC8 INTERGROUP TRIAL (2012) (10)
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives. (1999) (9)
Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. (2016) (9)
LBA13PHASE III RECOURSE TRIAL OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (2014) (9)
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. (2021) (9)
Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2015) (9)
Intestinal metaplasia in gastric malignancy: a comparison between carcinoma and lymphoma (1998) (9)
546 Advanced gastric cancer: Comparison of FAMTX (5FU, adriamycine, methotrexate) versus elf (etroposide, 5 FU, leucovorin) versus FUP (infusional 5 FU + cisplatin). Results from an eortc trial of the GITCCG and the arbeitsgemeinschaft für innere onkologie (AIO) (1995) (9)
Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR). (2012) (9)
Chemotherapy plus cetuximab in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: A pooled analysis of the CRYSTAL and OPUS studies (2012) (9)
Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab) (2007) (9)
Activity of Cabozantinib (XL184) in Hepatocellular Carcinoma (HCC) Patients: Results From a Phase 2 Randomized Discontinuation Trial (RDT) (2012) (9)
517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC) (2017) (9)
(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. (2010) (9)
O-0017PREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE AND OXALIPLATIN VS. CAPECITABINE ALONE IN LOCALLY ADVANCED RECTAL CANCER: DISEASE FREE SURVIVAL AT INTERIM ANALYSIS (2014) (9)
Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial (2016) (8)
Su1432 I-SCAN Detects More Polyps in Lynch Syndrome (HNPCC) Patients: A Prospective Controlled Randomized Back-to-Back Study (2012) (8)
Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT-4 Study. (2016) (8)
3020 POSTER Preliminary efficacy of Bevacizumab with first-line Folfox, Xelox, Folfiri and fluoropyrimidines for mCRC: First BEAT trial (2007) (8)
O-0023PREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE AND OXALIPLATIN VS. CAPECITABINE ALONE IN LOCALLY ADVANCED RECTAL CANCER: RESPONSE TO THE LOCAL TREATMENT AFTER CHEMORADIATION AND SURGERY AS SECONDARY ENDPOINT (2013) (8)
Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial. (2017) (8)
Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. (2016) (8)
OC-0250: First results of the PETACC-6 randomized phase III trial in locally advanced rectal cancer (2014) (8)
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors. (2019) (8)
O-0026 Significant Relationship Between CA19-9 Kinetics and Overall Survival (OS) from a Phase 3 Trial in Advanced Pancreatic Cancer (APC). (2012) (8)
Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer. (2016) (7)
Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data (2008) (7)
More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer (2018) (7)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m) (2016) (7)
O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma (2020) (7)
DOSE ESCALATION TO RASH FOR ERLOTINIB PLUS GEMCITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER: THE PHASE II RACHEL (BO21128) STUDY (2012) (7)
Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl) (2012) (7)
Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model (2010) (7)
Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database. (2019) (7)
Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study. (2020) (7)
Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer (2007) (7)
JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy. (2015) (7)
2015 Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study (2015) (7)
PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER (2013) (7)
Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study. (2016) (7)
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. (2021) (7)
IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703. (2015) (7)
Association between EGFR gene copy number and KRAS status and impact on outcome prediction in colorectal cancer patients treated with cetuximab (2008) (6)
Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab (2006) (6)
Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial. (2013) (6)
Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial (2012) (6)
A phase III randomized controlled trial of panitumumab in patients with metastatic colorectal cancer: subset analyses in elderly patients and in patients with poor performance status. (2007) (6)
6088 Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study (2009) (6)
KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer. (2018) (6)
Belgian guidelines for HER2 testing in gastric cancer (2011) (6)
Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Updated safety results. (2010) (6)
XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC): Post-hoc analysis of a large phase II study (2004) (6)
Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. (2013) (6)
gastrointestinal tumours, colorectalNintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study (2016) (6)
Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC). (2013) (6)
CanStem303C trial: A phase III study of BBI-608 (napabucasin) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC) (2016) (6)
A phase I dose escalation study of BIBF 1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients (pts). (2010) (6)
Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059. (2016) (6)
Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study. (2018) (6)
A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer (1996) (6)
Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. (2017) (6)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two (2017) (6)
O-0021 Randomised Phase III Study of Bevacizumab + Chemotherapy Beyond Progression in Bevacizumab-Treated Patients with Metastatic Colorectal Cancer: TML Study Kras Subgroup Findings (2012) (6)
Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts. (2020) (5)
Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib (2013) (5)
Treatment of a Metastasis of a Rectal Carcinoma in the Greater Trochanter with the AO/ASIF Proximal Femoral Nail. A case report (2004) (5)
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) (2012) (5)
E13Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months (2015) (5)
O-020Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (2015) (5)
2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (5)
O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study (2016) (5)
Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials (2007) (5)
Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer (2001) (5)
A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2020) (5)
Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update (2012) (5)
O-0020OUTCOME ACCORDING TO TUMOR RAS MUTATION STATUS IN CRYSTAL STUDY PATIENTS WITH METASTATIC COLORECTAL CANCER RANDOMIZED TO FOLFIRI WITH OR WITHOUT CETUXIMAB AS FIRST-LINE TREATMENT (2014) (5)
Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). (2021) (5)
Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET). (2015) (5)
Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC). (2019) (5)
701 ‘Tomudex’ (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): First results of a phase III study (1995) (5)
Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. (2019) (5)
RECOURSE trial: Performance status at discontinuation in patients receiving trifluridine/tipiracil (TAS-102) (2016) (5)
Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. (2021) (5)
The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab (2008) (5)
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW. (2020) (4)
Colorectal Cancer Treated With Cetuximab Patients With Chemotherapy-Refractory Metastatic p . G 13 D Mutation With Outcome inKRASAssociation of Supplementary material (2010) (4)
BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT (2012) (4)
The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management (2012) (4)
DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease (2008) (4)
Distinctive chromosomal instability (CIN) patterns and its prognostic value in pancreatic neuroendocrine tumors (pNET). (2016) (4)
Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts) (2007) (4)
O-0017OBSERVED BENEFIT OF AFLIBERCEPT IN MCRC PATIENTS ≥65 YEARS OLD: RESULTS OF A PRESPECIFIED AGE-BASED ANALYSIS OF THE VELOUR STUDY (2013) (4)
Updated Survival and Safety Data From RADIANT-3-a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET) (2011) (4)
Abstract CT191: Mechanism of action of the farnesyltransferase inhibitor, tipifarnib, and its clinical applications (2019) (4)
AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1). (2021) (4)
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071). (2015) (4)
Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (2016) (4)
PIK 3 CAMutations Are Not aMajor Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer (2009) (4)
Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer (2004) (4)
Phase II pharmacokinetic (PK) and pharmacodynamic (PD) study of OSI-7904L in previously untreated patients (pts) with advanced gastric or gastroesophageal junction cancer (G/GEJC) (2005) (4)
1415 POSTER Blood Plasma VEGFA Analysis in the AVAGAST Randomized Study of First-line Bevacizumab (bev) + Capecitabine/Cisplatin (cape/cis) in Patients (pts) With Advanced Gastric Cancer (AGC) (2011) (4)
O-0006RAINBOW: A GLOBAL, PHASE 3, DOUBLE-BLIND STUDY OF RAMUCIRUMAB PLUS PACLITAXEL VERSUS PLACEBO PLUS PACLITAXEL IN THE TREATMENT OF GASTRIC CANCER FOLLOWING DISEASE PROGRESSION: WESTERN POPULATION SUBGROUP (2014) (4)
The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA). (2012) (4)
Fetal electrocardiogram measuring method and equipment (FEMME) (1987) (4)
PD-025RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment (2016) (4)
Progress With Biological Agents in Metastatic Colorectal Cancer Leads to Many Challenges (2006) (4)
Novel cytotoxic regimens in gastric cancer (2006) (4)
Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb). (2018) (4)
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study. (2018) (4)
MSI versus MSS sporadic colorectal cancers: Morphology, inflammation, and angiogenesis revisited (2014) (4)
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study. (2016) (4)
O-0012 Prognostic Factors of Overall Survival (OS) in Previously Treated Advanced Gastric Cancer (AGC): Analysis of the Phase 3 Granite-1 Trial (2012) (4)
Histopathological validation of lymph node staging in cancer of the esophagus and gastroesophageal junction with FDG-PET scan: a prospective study based on primary surgery with extensive lymphadenectomy (2000) (4)
Pancreatic and hepatobiliary cancers: New treatment possibilities for pancreatic and biliary tumours (2000) (4)
Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival. (2021) (4)
Validation of two gene-expression risk scores in a large colon cancer cohort and contribution to an improved prognostic method. (2012) (4)
Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3. (2021) (4)
Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database. (2017) (4)
Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. (2017) (4)
1412 POSTER Genetic Markers in Relation to Bevacizumab-induced Hypertension (2011) (3)
Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147. (2013) (3)
On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study. (2013) (3)
PD-0002KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB + FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS (2014) (3)
Prognosis of stage II and III colon cancer treated with adjuvant 5-fl uorouracil or FOLFIRI in relation to microsatellite status : results of the PETACC-3 trial † (2014) (3)
Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP). (2014) (3)
Microarray ANALYSIS of t(11;18)(Q21;Q21)-positive and -negative gastrointestinal MALT lymphomas. (2010) (3)
P-0173PHASE 3 TRIAL OF GEMCITABINE AND TH-302 COMPARED WITH GEMCITABINE AND PLACEBO IN PATIENTS WITH PANCREATIC ADENOCARCINOMA: THE MAESTRO TRIAL (2013) (3)
Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment (2013) (3)
303 Capecitabine plus oxaliplatin (XELOX): findings from a human colon cancer xenograft model and a phase II clinical trial in patients with metastatic colorectal cancer (MCRC) (2003) (3)
LBA-01Survival outcomes according to body mass index (BMI): results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer (mCRC) (2015) (3)
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer (2008) (3)
Raltitrexed/gemcitabine in patients with advanced biliary tract adenocarcinoma: a phase II study (2003) (3)
408 Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC) (2010) (3)
Highlights in Gastrointestinal Oncology (2006) (3)
12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. March 11-13, 2015, Barcelona, Spain: Abstracts (2015) (3)
PD-003Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC) (2016) (3)
Identification of a Poor-Prognosis BRAF-Mutant Like Populationof Patients With Colon Cancer. Journal of Clinical Oncology,30(12):12BB-1295, 2012 (2012) (3)
Colon cancer: management of locoregional disease (2008) (3)
Standard treatment for metastatic colorectal cancer (CRC) (2006) (3)
2120 Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI + cetuximab in the CRYSTAL study (2015) (3)
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. (2020) (3)
Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. (2015) (3)
Serial positron emission tomography (PET) to assess the response of preoperative induction chemoradiotherapy in advanced esophageal cancer in relation to survival (2001) (3)
O-012Prognosis of lung metastases in patients with metastatic colorectal cancer: an ARCAD meta analysis (2016) (3)
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: an open-label, multicenter Phase I study (2007) (3)
432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164 (2021) (3)
Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS. (2019) (3)
Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a phase 3 randomized controlled trial (2006) (3)
Positron emission tomography (PET) compared to EUS & spiral CT in staging of patients with potentially operable esophageal carcinoma (2000) (3)
Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial. (2016) (3)
6569 POSTER Updated Overall Survival Data From a Phase III Study of Sunltlnlb Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET) (2011) (3)
Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: RADIANT-3 subgroup analysis. (2013) (3)
P-106Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study (2015) (3)
O-011Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC) (2015) (3)
The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona (2014) (3)
Kras mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab (2011) (3)
Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study. (2017) (3)
METASTATIC COLORECTAL CANCER: ANALYSIS OF PREDICTIVE UTILITY IN THE CRYSTAL AND OPUS STUDIES (2012) (3)
3032 POSTER Health-related Quality of Life in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Cancer With High HER2 Expression Levels – Exploratory Analysis of the Phase III ToGA Study (2011) (2)
Comparison of endorectal ultrasound and CT-scan in the preoperative staging of colorectal cancer (1998) (2)
Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study. (2016) (2)
PD-0029CHEMOTHERAPY PLUS CETUXIMAB AS CONVERSION TREATMENT FOR PATIENTS WITH INITIALLY UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER (2013) (2)
Phase I study of EMD 525797 (DI17E6), an antibody targeting ανβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer. (2012) (2)
Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI. (2017) (2)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. (2015) (2)
Clinical Cancer esearch ing , Diagnosis , Prognosis even-Gene Set Associated with Chronic Hypoxia of R gnostic Importance in Hepatocellular Carcinoma (2010) (2)
Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study (2016) (2)
Future developments with 'Tomudex' (raltitrexed) (1997) (2)
Computed tomographic colonography. (2005) (2)
538P Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC) (2021) (2)
CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy. (2020) (2)
Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET) : A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data (2014) (2)
QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy—Results from the TASCO1 phase II study. (2019) (2)
Push enteroscopy has a higher yield for the diagnosis of the source of occult bleeding than sonde-type enteroscopy (1994) (2)
93 TiPPatient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma (2017) (2)
Cetuximab in combination with irinotecan in patients after irinotecan failure: An integrated analysis of four studies from different geographic regions (2008) (2)
O2–035SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIAL (2013) (2)
2150 Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (2)
Relevance of the stroma in pancreatic ductal adenocarcinoma and its challenges for translational research (2017) (2)
Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial. (2014) (2)
Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab. (2019) (2)
D04Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer (2016) (2)
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. (2014) (2)
Self-Rated Pain Assessment by Patients With HER2-Positive Advanced Gastric/GEJ Cancer Treated With 5-FU/Capecitabine and Cisplatin With or Without Trastuzumab: Exploratory QOL Analysis From the Phase III ToGA Study (2011) (2)
Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial. (2020) (2)
O-0001PHASE 2 DOUBLE-BLIND, PLACEBO–CONTROLLED TRIAL OF DASATINIB ADDED TO GEMCITABINE FOR SUBJECTS WITH LOCALLY-ADVANCED PANCREATIC CANCER (LAPC) (2014) (2)
PD-0008COMPREHENSIVE KRAS AND NRAS MUTATION ANALYSIS: PREDICTIVE BIOMARKERS IN A PHASE 3 PANITUMUMAB MONOTHERAPY STUDY OF METASTATIC COLORECTAL CANCER (MCRC) (2013) (2)
PD-012Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC) (2016) (2)
Time to grade ≥3 adverse events in pts receiving trifluridine/tipiracil (TAS-102). (2017) (2)
Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102) (2016) (2)
O-0020 Bevacizumab + Chemotherapy Beyond First Progression in Metastatic Colorectal Cancer Patients Previously Treated with Bevacizumab-Based Therapy: TML Study Subgroup Findings (2012) (2)
Outcome prediction to cetuximab in advanced colorectal cancer: Analysis of EGFR and HER2 gene copy number by fluorescence in situ hybridization (2007) (2)
232TiPKEYNOTE-061: Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (2015) (2)
Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts) (2007) (2)
Locoregional Tumor Therapy (2018) (2)
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. (2015) (2)
2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer (2015) (2)
Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database. (2020) (2)
The role of FDG-PET in the design of the radiation fields for patients with advanced esophageal cancer (2002) (2)
Peripheral blood monocytes as biomarkers for colorectal cancer. (2013) (2)
Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. (2020) (2)
Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp). (2021) (2)
PLS. plenary session (2012) (2)
3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II–III COC patients (PETACC 3–EORTC 40993–SAKK 60/00) (2007) (2)
Updated Overall Survival Data From a Phase III Study of Sunitinib Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET) (2011) (2)
Analysis of hematologic adverse events (HeAEs) in trifluridine/tipiracil (FTD/TPI)-treated patients (pts) with or without renal/hepatic impairment (RI/HI): Pooled safety analyses from TAGS and RECOURSE. (2020) (2)
P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (2020) (2)
Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment. (2013) (2)
A phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients (Pts) with metastatic colorectal cancer (CRC) to investigate the interaction between the agents. (2005) (2)
P-105Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study (2015) (2)
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies. (2019) (2)
Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study (2008) (2)
LBA-10MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach (2015) (2)
Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. (2021) (2)
Analysis of Progression-Free Survival (PFS) by Prior Chemotherapy Use and Updated Safety in RADIANT-3: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial of Everolimus in Patients with Advanced Low- or Intermediate-Grade Pancreatic Neuroendocrine Tumors (pNET) (2012) (2)
Correction: Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline (Endoscopy (2019) 51 DOI: 10.1055/a-0831-2522) (2019) (1)
PD-030Prospective non-interventional study to collect data on the use of bevacizumab and conventional chemotherapy for the treatment of previously untreated metastatic colorectal cancer in patient's ≥70 years (2016) (1)
Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. (2013) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)--Findings from the ACCENT dataset. (2010) (1)
QTWIST analysis in the RECOURSE trial. (2017) (1)
POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
572PPROGNOSTIC VALUE OF KRAS MUTATIONS IN STAGE III COLON CANCER: POST-HOC ANALYSES OF THE PETACC8 PHASE III TRIAL (2014) (1)
Overall Survival (OS) Analysis of Sunitinib (SU) after Adjustment for Crossover (CO) in Patients with Pancreatic Neuroendocrine Tumors (NET) (2011) (1)
MIS1. colorectal cancer (2012) (1)
FDG-PET for staging recurrent esophageal cancer (EC) (2000) (1)
PD-0429: Combining chemoradiation with COX-2 inhibitors in rectal cancer: clinical and translational data of a phase II study (2014) (1)
PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) (2011) (1)
Somatostatin receptor radionuclide therapy : a promising tool in the treatment of neuroendocrine tumours (2010) (1)
Abstract 289: Associations between germline genotype and efficacy and safety outcomes in a phase III study of sunitinib (SU) and FOLFIRI in metastatic colorectal cancer (mCRC) (2011) (1)
Gastrointestinal tumors, colorectal (2012) (1)
O-010KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer (2015) (1)
Squamous papilloma of the oesophagus and human papilloma virus (1994) (1)
POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC). (2013) (1)
Patient reported abdominal pain as a surrogate of the clinical benefit of tipifarnib in pancreatic cancer patients. (2019) (1)
Induction therapy for potential T4 oesophageal carcinoma: a plea for continued surgical exploration (1996) (1)
O-0016RAINBOW: GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF RAMUCIRUMAB PLUS PACLITAXEL VS PLACEBO PLUS PACLITAXEL PATIENTS WITH PREVIOUSLY TREATED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA – PATIENT-REPORTED OUTCOMES AND PERFORMANCE STATUS (2014) (1)
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer (2012) (1)
Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials. (2020) (1)
Quality control (QC) tissue array for the prospective rvaluation of translational research projects. A program of the EORTC GI and RGB Groups (2005) (1)
Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. (2020) (1)
Docetaxel in gastric cancer (2004) (1)
Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database. (2018) (1)
Trastuzumab for gastric cancer treatment – Authors' reply (2010) (1)
Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition (2008) (1)
Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. (2018) (1)
Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC). (2021) (1)
Additional value of positron emission tomography (PET) with fluoro-deoxy glucose (FDG) in recurrent colorectal cancer: A study in 103 patients (1998) (1)
529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors (2021) (1)
New approaches for the treatment of colorectal cancer in the adjuvant setting (2004) (1)
POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). (2020) (1)
ASSOCIATIONS BETWEEN GERMLINE GENOTYPE AND EFFICACY AND SAFETY OUTCOMES IN A PHASE III STUDY OF SUNITINIB AND FOLFIRI IN METASTATIC COLORECTAL CANCER (MCRC) (2011) (1)
Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P). (2020) (1)
Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC). (2019) (1)
Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial. (2020) (1)
Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS). (2019) (1)
Use of tumor size decrease at 6 weeks (w) to predict response (OR), time to progression (TTP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) (BOND trial) (2008) (1)
UFT and leucovorin in metastatic colorectal cancer: clinical insights (2003) (1)
Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data. (2015) (1)
The utility of whole-body positron emission tomography (PET) with 18-f-fluoro-deoxy-d-glucose (FDG) for diagnosis of recurrent gastric cancer (2001) (1)
Corrigendum to “Does a patient’s self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?” [Eur. J. Cancer 42 (2006) 42–49] (2007) (1)
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): successful treatment of a patient with disseminated esophageal and hypopharyngeal papillomatosis (1994) (1)
Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study. (2016) (1)
A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). (2018) (1)
Global BRAF testing practices in metastatic colorectal cancer. (2021) (1)
FDG-PET for preoperative lymph node (N) staging of esophageal cancer (1999) (1)
Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab (2012) (1)
Efficacy and safety of panitumumab across five clinical studies in patients with metatastic colorectal cancer. (2007) (1)
Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy. (2010) (1)
Effect of number of prior lines versus prior regimens in pts receiving trifluridine/tipiracil (TAS-102). (2017) (1)
Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859. (2021) (1)
Abstract LB-447: Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab (2012) (1)
SO-3 Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial (2020) (1)
IS9. colorectal cancer (2012) (1)
Cell-of-origin based intrahepatic cholangiocarcinoma classification corresponds to Kras mutation status as well as cetuximab efficacy (2013) (1)
Efficacy and safety of gemcitabine in combination with TH-302 compared with gemcitabine in combination with placebo in previously untreated patients with metastatic or locally advanced unresectable pancreatic adenocarcinoma: The MAESTRO trial. (2013) (1)
Everolimus plus Octreotide LAR versus Placebo plus Octreotide LAR in Patients with Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2) (2011) (1)
Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study. (2013) (1)
O-0015 Survival According to Prognostic Risk Factors in Patients Receiving First-Line Chemotherapy Plus Cetuximab in the Crystal and Opus Studies (2012) (1)
PD-0022 Aflibercept Versus Placebo in Combination with Folfiri in Previously Treated Metastatic Colorectal Cancer: Mean Overall Survival for Subgroups from Velour (2012) (1)
1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer (2021) (1)
The Treatment of Metastatic Colorectal Cancer (2006) (1)
2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC) (2015) (1)
Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) (2011) (1)
Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power) (2019) (1)
PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer (2009) (1)
Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with Bev-Based Therapy: Overall Survival Subgroup Findings from ML18147 (2012) (1)
Adjuvant chemotherapy for stage III colon cancer in 2005: where are we now? (2005) (1)
Angiomatous extension of intestinal type carcinoma relates to microvessel density and VEGF-expression, when compared to diffuse type carcinoma in oesophageal, proximal and distal gastric cancer (2001) (1)
Have we made progress with biological agents in metastatic colorectal cancer? (2007) (1)
Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI (2016) (1)
The Role of Chemotherapy and Radiotherapy in the Management of Adenocarcinoma of the Gastroesophageal Junction and Lower Esophagus (2007) (1)
O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) (2012) (1)
Upregulated expression of VEGF and CA IX correlate with the vascular metastasis pattern of intestinal type carcinoma (2003) (1)
Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab. (2019) (1)
Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC) (2016) (1)
Early metabolic response evaluation on PET-CT after a single cycle of chemotherapy in patients with cT3-4N0/+ oesophageal or GE-junction cancer subsequently treated by neoadjuvant chemoradiotherapy (2010) (1)
How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database. (2020) (1)
E04Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study (2015) (1)
PD-0030TIME COURSE OF ADVERSE EVENTS IN THE VELOUR TRIAL (2013) (1)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023) (1)
Primary gastric lymphoma: proper treatment requires proper classification (1995) (0)
Phase II, multicenter, open-label, proof of concept study of tasquinimod in patients with advanced/metastatic hepatocellular (HCC), ovarian (OC), renal cell (RCC) and gastric (GC) carcinomas. (2013) (0)
The diagnostic problem of gasric unusual lymphoid infiltrates is not solved by the scoring scale of Wotherspoon (1999) (0)
Should Biological Targeted Agents be Combined with Preoperative Chemoradiation in Rectal Cancer? An Update (2018) (0)
Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database. (2015) (0)
PD-0025 Evaluation of Codon 12 and 13 KRAS Mutations as Biomarkers of Response to Panitumumab in Patients with Metastatic Colorectal Cancer (2012) (0)
The adjuvant treatment of gastric cancer (2005) (0)
Hybrid Imaging Reveals Improved Absorbed Dose from Selective Internal Radiation Treatment by Using an Anti-Reflux Catheter (2020) (0)
Ga-68-DOTATOC PET/CT after 1 cycle of PRRT with Y-90-DOTATOC visualizes changes in somatostatin receptor availability in neuroendocrine tumours (2010) (0)
Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers. (2021) (0)
OC-0253: Bevacizumab with chemoradiation in rectal cancer: clinical and translational results of the AXEBeam trial (2014) (0)
SY17-4 Immuno-oncology agents for advanced gastric cancer (2021) (0)
Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer? (2004) (0)
PD-0019 Benefit of Panitumumab (pmab) as Monotherapy in Patients with WT KRAS mCRC: A Number-Needed-To-Treat (NNT) Analysis (2012) (0)
UFT/LV: future directions (2003) (0)
Mutation analysis in Belgian familial colorectal cancer kindreds: High proportion of novel mutations in the mismatch repair genes (2000) (0)
Does blood glucose level normalization improve the accuracy of PET-based response prediction in rectal cancer? (2016) (0)
No deleterious effect of pretreatment with everolimus and/or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT (2019) (0)
EANM Springer Prizes 2021 awarded at EANM 2021 (2022) (0)
How usefull is the Goseki grading system besides its prognostical value (1996) (0)
120 A 7 GENE SET ASSOCIATED WITH CHRONIC HYPOXIA OF UNIVERSAL PROGNOSTIC IMPORTANCE IN HEPATOCELLULAR CARCINOMA (2010) (0)
Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database. (2017) (0)
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (2015) (0)
Squamous papilloma of the oesophagus: diagnosis and treatment (1996) (0)
Treatment of bleeding gastrointestinal telangiectasias with estragen-progesterone (1989) (0)
Preoperative (chemo)radiotherapy for rectal cancer: Influence of treatment schedule on locoregional control (2001) (0)
Abstract No. 78: Evaluation of a novel percutaneous isolated liver perfusion (PILP) system in a porcine model (2010) (0)
P-284Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup (2015) (0)
437P Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142 (2021) (0)
Circumpherential resection margin involvement - a postoperative predict of survival in distal oesophageal and cardia cancer (2003) (0)
Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database. (2016) (0)
Assessing outcome differences in the second line treatment of metastatic colorectal cancer (mCRC): An ARCAD analysis comparing sequence after first line trials (SAFL) and dedicated second line trials (DSLT). (2017) (0)
AVAPLUS: Impact of geriatric assessment on first-line treatment duration (TD) and progression free survival (PFS) in mCRC patients ≥ 70 years (2016) (0)
Intrinsic Resistance To the Antiproliferative Effects of Azd6244 a Selective Mek1/2 Inhibitor Is Associated With Concomitant K-ras and Pi3kca Gene Mutations in Colorectal Cancer Cells (2010) (0)
Repeated liver percutaneous isolated localized perfusion (liver-PILP) with occlusion ballons and a catheter-based stent-graft-like perfusion device (2011) (0)
Sections Vol. 66, 2002 (2003) (0)
O-013A global risk gene score predicts early and late tumor recurrence after resection of hepatocellular carcinoma (2015) (0)
Response assessment with positron emission tomography (PET) to induction chemoradiation therapy in patients with locally advanced esophageal cancer (EC) (2004) (0)
Response prediction to EGFR-targeted therapies in colorectal cancer (2006) (0)
Contents Vol. 66, 2002 (2002) (0)
First-line chemotherapy plus cetuximab in patients grouped according to prognostic risk factors: Analysis of the CRYSTAL and OPUS studies. (2012) (0)
Impact of anorectal dysfunction in rectal cancer patients. (2010) (0)
The use of diffusion weighted mri for the prediction of pathological response in rectal cancer treated with preoperative chemoradiotherapy (2010) (0)
35 Final results and survival data of a large International Trial confirm palliative benefits of ‘TOMUDEX’ (Raltitrexed) in advanced colorectal cancer (ACC) (1996) (0)
PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp). (2021) (0)
Abstract LB-78: Pharmacogenomic analysis of a phase III trial of gemcitabine/axitinib versus gemcitabine/placebo in patients with advanced pancreatic cancer (2010) (0)
Moyamoya Disease and Moyamoya Syndrome (2009) (0)
TP, TS AND DPD AS POTENTIAL PREDICTORS OF OUTCOME FOLLOWING CAPECITABINE PLUS OXALIPLATIN (XELOX) VS. BOLUS 5-FLUOROURACIL/LEUCOVORIN (5-FU/LV) AS ADJUVANT THERAPY FOR STAGE III COLON CANCER: UPDATED BIOMARKER FINDINGS FROM STUDY NO16968 (XELOXA) (2012) (0)
The old antibiotic acriflavine inhibits epithelial-to-mesenchymal transition and the unfolded protein response thereby resensitizing resistant hepatoma cells to sorafenib (2016) (0)
P0261 : A global risk gene score predicts early and late tumor recurrence after resection of hepatocellular carcinoma (2015) (0)
SYT and EWS abnormalities are recurrently occurring in poorly differentiated gastroesophageal cancers (2013) (0)
Levels of amphiregulin and epiregulin expression correlate with overall survival in colorectal cancer treated with cetuximab (2007) (0)
Long-term impact of anorectal dysfunction after rectal cancer surgery (2011) (0)
1058 Cox-2 inhibition in gastrointestinal cancer (2003) (0)
The neo-adjuvant and adjuvant treatment of gastric cancer (2005) (0)
HPMPC: A new antiviral agent with activity against human papillomavirus (1994) (0)
Can Helicobacter pylori eradication therapy reasonably be considered as appropriate for every low grade malt lymphoma of the stomach (1997) (0)
Gender and chemotherapy-related toxicity in colon cancer: an analysis of the PETACC-3 trial conducted by the EORTC GI-group (2016) (0)
Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC). (2015) (0)
Chemotherapy Plus Cetuximab in Patients with Colorectal Metastases Grouped by Site: A Pooled Analysis of the Crystal and OPUS Studies (2012) (0)
EP-1282: Does blood glucose level normalisation improve PET-based response prediction in rectal cancer? (2016) (0)
Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study (2017) (0)
Reduction of kidney toxicity from 90Y-DOTATOC PRRT through individualized 111In-pentetreotide dosimetry (2013) (0)
PD-0568 PHASE II STUDY OF NEO ADJUVANT TREATMENT WITH AVASTIN, XELODA AND ELOXATIN IN RECTAL CANCER (AXE BEAM) (2012) (0)
141OEfficacy outcomes by age from 5 observational or phase-4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC) (2015) (0)
Mutations of the APC gene in FAP-associated and sporadic desmoid tumors. A common pathogenesis? (1999) (0)
Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB) (2018) (0)
Current Treatment Standards in Metastatic Colorectal Cancer — The Role of Anti-epidermal Growth Factor Antibodies (2007) (0)
PD-0025DISEASE PROGRESSION PATTERNS/OUTCOME BY DISEASE EXTENT FOLLOWING BEVACIZUMAB + CHEMOTHERAPY BEYOND FIRST DISEASE PROGRESSION IN PREVIOUSLY TREATED MCRC (ML18147 STUDY) (2013) (0)
Does Integrating Functional Imaging and Molecular Markers Contribute to a Better Prediction of the Tumoral Response After Preoperative Chemoradiation Therapy for Rectal Cancer (2016) (0)
UFT/LV: a novel concept in the chemotherapy of metastatic colorectal cancer (2003) (0)
Treatment and Survival Outcomes by Age Following Second-Line Therapy for Metastatic CRC (mCRC): Analysis of 13,149 Patients from the ARCAD Clinical Trials Program (2021) (0)
O-0022COMPARISON OF DOCETAXEL, FLUOROURACIL AND OXALIPLATIN OR CISPLATIN WITH OTHER MODIFIED SCHEDULES: A NEW THERAPEUTIC INDEX IN ADVANCED GASTRIC CANCER (2013) (0)
Small Bowel tumors. Other Treatments (2008) (0)
Cytoplasmic accumulation of p53 occurs in intestinal metaplasia associated with gastric ulcers but not with duodenal ulcers (1998) (0)
ASSESSMENT OF TUMOR GENOTYPES IN METASTATIC COLORECTAL CANCER (MCRC): MUTATIONS BEYOND KRAS CODONS 12 AND 13 AS PREDICTIVE BIOMARKERS OF RESPONSE TO PANITUMUMAB (PMAB) IN A RANDOMIZED, PHASE 3 STUDY (2011) (0)
IIIA.1 The role of new targeted agents in metastatic colorectal cancer (2006) (0)
Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers. (2013) (0)
CRS+HIPC to treat peritoneal carcinomatosis from upper GI Cancer : 1-year analysis of the HIPCUPP-trial (2012) (0)
EGFR and HER2 in colorectal cancer: Analysis of gene copy number and protein expression over disease progression. Does intratumoral heterogeneity matter? (2007) (0)
Reply to M.J. Rother (2011) (0)
Is there a role for chemotherapy in the adjuvant treatment of rectal cancer (2001) (0)
P-80 TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (2019) (0)
Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study (2012) (0)
Capecitabine, a n O ral F luoropyrimidine C arbamate W ith Substantial A ctivity i n A dvanced C olorectal C ancer: Results o f a R andomized P hase I I S tudy (2000) (0)
Adjuvant therapy for pancreatic cancer: current status and future directions (2004) (0)
Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database. (2017) (0)
Are lympho-epithelial lesions the diagnostic hallmark of gastric marginal zone cell lymphomas (1999) (0)
Induction chemo-radiotherapy for clinical T4 esophageal carcinoma (1998) (0)
774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors (2022) (0)
The prognostic value of health related quality of life in colorectal cancer patients: A multivariate analysis using a bootstrap model-averaging approach (2005) (0)
Subject Index Vol. 30, Suppl. 2, 2012 (2012) (0)
Abstract CT066: Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (2017) (0)
PROGNOSTIC AND PREDICTIVE FACTORS OF THE RESPONSE TO ADJUVANT CHEMOTHERAPY IN RESECTABLE GASTRIC CANCER: RESULTS FROM THE GASTRIC META-ANALYSIS (2011) (0)
Authors & Collaborators _ RAISE study (2015) (0)
Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-blind, Placebo-controlled Phase III Trial of Nintedanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Advanced Colorectal Cancer Refractory to Standard Treatment (2015) (0)
ISY-17-3Subgroup analysis in RAISE: a phase III study of FOLFIRI + ramucirumab or placebo in patients with advanced mCRC (2016) (0)
The adventitial circumferential resection margin is an independent prognostic marker in T3 oesophageal and cardiac adenocarcinomas (2003) (0)
Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade. (2020) (0)
A global risk gene score predicts early and late tumor recurrence after resection of hepatocellular carcinoma (2015) (0)
Safety and activity of ziv-aflibercept in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with colorectal cancer previously treated with irinotecan: Results from a phase 1 study. (2014) (0)
Does radioimmunoguided surgery (RIGS) improve intra-operative diagnosis and treatment of primary colorectal cancer (PCRC) preliminary data on 30 patients (1997) (0)
GUIDELINES COLON CANCER EXPERT PANEL (2014) (0)
P2-5-22LUME-Colon 1: a randomized phase III study of nintedanib vs placebo in patients with advanced colorectal cancer (2015) (0)
Subject Index Vol. 67, 2004 (2005) (0)
Anal carcinoma in Crohn's disease: Late diagnosis, a potential risk factor in poor outcome (1997) (0)
What have we learned and where are we going in the treatment of colorectal and gastric cancer (2004) (0)
Staging and follow-up of patients operated with radioimmunoguided surgery (RIGS) for colorectal cancer (2001) (0)
Clinical Approaches of Emergencies in Neuroendocrine Tumors (2014) (0)
Targeted agents in gastrointestinal cancer: a reality in clinical practice (2008) (0)
KRAS mutational status is associated with clinical response in patients with metastatic colorectal cancer receiving panitumumab monotherapy (2007) (0)
Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database. (2019) (0)
734 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors (2022) (0)
New Analysis of CRYSTAL Results Supports Patient Selection According to RAS Mutation Status to Maximize Benefit from CET Therapy (2014) (0)
PD-0129: FDG-PET/CT for prediction and assessment of pathological response to induction CRT for esophageal carcinoma (2014) (0)
Progress in the management of chemorefractory colorectal cancer (2012) (0)
Left- vs Right-Sided Colon Cancers (2017) (0)
Upper gastrointestinal cancers: Are all carcinomas truly carcinomas? (2014) (0)
91 INVITED Optimal strategy for integration of biologics in treatment of metastatic colorectal cancers (2007) (0)
O-0006COMPARISON OF DIAGNOSTIC ACCURACY OF 111IN-PENTETREOTIDE SPECT AND 68GA-DOTATOC PET: A LESION-BY-LESION ANALYSIS IN PRRT-PATIENTS (2013) (0)
Bevacizumab in Combination With Chemotherapy as First-LineTherapyinAdvancedGastricCancer:ABiomarker EvaluationFromtheAVAGASTRandomizedPhaseIIITrial (2012) (0)
Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases. (2021) (0)
Adjuvant chemoradiation after curative resection for pancreatic cancer is feasible: Results of a randomised EORTC/FFCD/GERCOR study (2008) (0)
Gastric unusual lymphoid infiltrates - as marginal zone cell lymphomas (MZCL) - may regress after Helicobacter pylory (Hp) eradication (2001) (0)
Body weight loss (BWL) as a prognostic/predictive factor in previously treated patients (pts) with metastatic gastric or gastroesophageal junction cancer (mGC/GEJC): Post-hoc analyses of the phase III tags trial. (2021) (0)
Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. (2020) (0)
Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database. (2018) (0)
Diffuse and/or superficial p53 expression in Barrett mucosa correlates with severe dysplasia (2005) (0)
Does PREDIST-based response evaluation allow for treatment individualization after chemoradiotherapy for rectal cancer? (2015) (0)
Consistent safety and efficacy results in 2 study populations treated with irinotecan (CPT-11) for metastatic colorectal cancer (MCRC) resistant to 5-FU (1997) (0)
Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2016) (0)
Should Biologic Targeted Agents Be Combined with Preoperative Chemoradiation in Rectal Cancer (2012) (0)
FIRST-LINE CHEMOTHERAPY PLUS CETUXIMAB IN PATIENTS GROUPED ACCORDING TO PROGNOSTIC RISK FACTORS: ANALYSIS OF THE CRYSTAL AND OPUS STUDIES (2012) (0)
Belgian Guidelines for HER2testing in gastric cancer (2011) (0)
2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer (vol 63, pg 11, 2016) (2016) (0)
O-0010AXE BEAM: NEO-ADJUVANT TRIPLET VERSUS DOUBLET THERAPY WITH RADIATION AND TOTAL MESORECTAL EXCISION FOR LOCALLY ADVANCED RECTAL CANCER – A RANDOMIZED PHASE II STUDY AT THE END OF RECRUITMENT (2014) (0)
Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities (2014) (0)
MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer (2021) (0)
PD-008Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study (2016) (0)
2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD and RAINBOW) (2015) (0)
Tissue biomarkers in colon cancer (COC): The translational study on a phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (PETACC 3-EORTC 40993-SAKK 60/00) (2007) (0)
68Ga-DOTATOC uptake at baseline predicts good prognosis after PRRT in neuroendocrine tumors patients (2015) (0)
Pre-PRRT Uptake on 68Ga-DOTATOC predicts good prognosis in neuroendocrine tumor patients (2015) (0)
Transcriptional activation of Tcf/Lef in desmoids and colorectal cancer: Common molecular mechanisms leading to different tumor types (2000) (0)
2070 Is PREDIST-based response assessment an accurate selection tool for organ-preserving strategies after chemoradiotherapy for rectal cancer? (2015) (0)
Neuroendocrine tumours (NETS) (2016) (0)
Are differences in inflammatory response responsable for a different progression towards neoplasia (1996) (0)
2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study (2015) (0)
6514 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial (2009) (0)
D17Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial (2016) (0)
Multidisciplinary rectal cancer treatment: "Looking for an European Consensus" (2009) (0)
Inhibition of epithelial-mesenchymal transition (EMT): treatment option for advanced pancreatic cancer (2015) (0)
Genetic Biomarkers for Anti-angiogenic Therapies – a Race to Report (2010) (0)
EP-2055: Fibro-inflammatory circulating proteins as biomarkers for response in locally advanced rectal cancer (2016) (0)
Pharmacogenomics in a trial of gemcitabine/axitinib compared with gemcitabine/placebo in advanced pancreatic cancer (2010) (0)
34 oral: The Role of 18FDG-PET -CT In Response Prediction Before, During and After Neoadjuvant Chemoradiotherapy for Rectal Cancer (2010) (0)
Contents Vol. 67, 2004 (2005) (0)
Adjuvant chemoradiation alone versus chemoradiation after curative resection for pancreatic cancer: feasibility results of a randomised EORTC/FFCD/GERCOR study (40013/22012/0304) (2008) (0)
Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns. (2020) (0)
Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database. (2021) (0)
HPMPC treatment of a patient with esophageal and hypopharyngeal papillomatosis (1994) (0)
Like low grade marginal zone B-cell lymphomas (MZCL), atypical lymphoid infiltrates in stomach may regress after Helicobacter Pylori eradication (2001) (0)
379 POSTER The role of Src-family kinases in the activation of the EGFR following chemotherapy (2006) (0)
Correlation of dynamic 68Ga-DOTATOC PET/CT parameters with static image parameters in neuroendocrine tumor patients during PRRT (2013) (0)
S0266 Sulindac and Eflornithine Combination Delays the Need for Lower Gastrointestinal Surgery in Familial Adenomatous Polyposis: CPP FAP-310 Trial (2020) (0)
Original Paper 'Tomudex' (ZD1694): Results ofa Randomised Trial in Advanced Colorectal Cancer Demonstrate Efficacy and Reduced Mucositis and Leucopenia (1995) (0)
Induction therapy for potential T4 oesophageal carcinoma: a plea for continued exploration (1996) (0)
Baseline characteristics in the international, open-label, early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb). (2018) (0)
Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data (2015) (0)
Acriflavine inhibits the epithelial-to-mesenchymal transition in vitro in liver and pancreatic cancer cells: restoring the phenotype and drug sensitivity and reducing ATF4 mediated stress response (2016) (0)
P-0212IMPACT OF GERIATRIC ASSESSMENT ON TREATMENT DECISIONS AND FOLLOW-UP IN OLDER COLORECTAL CANCER PATIENTS (2013) (0)
Subject Index Vol. 66, 2002 (2003) (0)
TIPSS placement in the digestive oncology setting (2007) (0)
Influence of intestinal flora on the development of adenomas in the APC1638N mouse (1999) (0)
ENETS News Letter (2015) (0)
Targeted Oncology: a target for oncologists (2006) (0)
402 Pegasus GI, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with anti-cancer agents of participants with advanced and metastatic gastrointestinal cancer (2021) (0)
Heterogeneity of EGFR and HER2 gene status by fluorescent in situ hybridization in colorectal cancer (2006) (0)
304 Current chemotherapy options for advanced disease (2009) (0)
O ral C apecitabine C ompared W ith I ntravenous Fluorouracil P lus L eucovorin i n P atients W ith M etastatic Colorectal C ancer: R esults o f a L arge P hase I II S tudy (2001) (0)
Benefit of routine imaging after curative colorectal cancer treatment (2006) (0)
Radio-immuno-guided sugerty for colorectal cancer. A (immuno) histologic analysis of 562 lymph nodes from 44 patients (1999) (0)
Targeting the epidermal growth factor receptor in conjunction with Oxaliplatin (2004) (0)
O-0008ABITUZUMAB COMBINED WITH CETUXIMAB PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN ALONE, AS SECOND-LINE TREATMENT FOR PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: THE POSEIDON PHASE I/RANDOMIZED PHASE II TRIAL (2014) (0)
Microsatellite instability versus microsatellite stability in colon carcinoma: documentation of tumour heterogeneity and inflammation (2015) (0)
PG 2.01 Differentiating colon cancer by clinical criteria (2012) (0)
Instability of EGFR gene status during progression of colorectal cancer (2007) (0)
Unmet Medical Need in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutations: A Review (2020) (0)
Validation of a model of drug-induced aggressive liver cancer: gene expression and tumor recurrence (2016) (0)
Benefit-risk evaluation of ziv-aflibercept in combination with irinotecan-fluoropyrimidine-based chemotherapy (FOLFIRI) from the VELOUR trial using multicriteria decision analysis (MCDA). (2013) (0)
Long term survival data from EORTC study 40983 : Perioperative chemotherapy for resectable liver metastases from colorectal cancer (2012) (0)
La adición de aflibercept a fluorouracilo, ácido folínico e irinotecan mejora la supervivencia en un ensayo aleatorizado fase III en pacientes con cáncer colorrectal metastásico tratados previamente con un régimen basado en oxilaplatino (2013) (0)
SENSITIVITY ANALYSES OF PROGRESSION-FREE SURVIVAL (PFS) OF AFLIBERCEPT-FOLFIRI VERSUS PLACEBO-FOLFIRI IN METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE VELOUR STUDY (2012) (0)
Mortality A ssociated W ith I rinotecan P lus B olus Fluorouracil/Leu covorin: S ummary F indings o f a n Independent P anel (2001) (0)
OC-07: Clinical and Molecular Effects of Treatment with Bevacizumab, Capecitabine and Oxaliplatin in Rectal Cancer (2012) (0)
Ga-68-DOTATOC PET has a higher sensitivity, on a lesion-by-lesion comparative analysis, than In-111-pentetreotide SPECT in neuroendocrine tumor patients (2013) (0)
Diagnosis and treatment with endoscopy (1994) (0)
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2013) (0)
2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevaci (2015) (0)
Chemotherapy-induced peripheral neuropathy: From symptomatology using quantitative sensory testing towards effective treatment (2021) (0)
Detection of gastric slow-wave propagation by cutaneous electrogastrography (1988) (0)
P-184 A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (2020) (0)
OC-0019: The role of functional imaging and molecular markers for organ-preserving strategies after CRT for rectal cancer (2015) (0)
Irinotecan as single agent in the treatment of colorectal cancer: results of phase II studies (1998) (0)
This is a repository copy of Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B (2019) (0)
Hepatoma cells acquiring sorafenib resistance show mesenchymal differentiation driven by DNA methylation and genetic rearrangements (2016) (0)
State-ofthe-art Integration of Multikinase Inhibitors in the Treatment of Gastrointestinal Cancers (2016) (0)
P-307Immunomodulatory switch maintenance therapy to improve overall survival in metastatic colorectal carcinoma: The phase 3 IMPALA study (2015) (0)
Dosimetry with 111In-Octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC (2011) (0)
2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC) (2015) (0)
PG 6.3 Is there a need for adjuvant chemotherapy after combined modality treatment (2014) (0)
The need for a new fluoropyrimidine in advanced gastric cancer treatment (2012) (0)
Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study. (2021) (0)
Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database. (2021) (0)
1111 POSTER The wide spectrum of cutaneous side effects of epidermal growth factor receptor inhibitors and their treatment: experience from a digestive oncology–dermatology collaboration (2007) (0)
Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. (2021) (0)
PharmaForum (2016) (0)
231TiPKEYNOTE-059: Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With E.j.d. Van Cutsem?

E.j.d. Van Cutsem is affiliated with the following schools: